Metamizol for the Treatment of Neoplastic Chronic Pain
TerminatedPhase 4NCT02181920
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Study to evaluate the efficacy of metamizole in reducing morphine requirements in patients with moderate to severe chronic cancer pain in comparison to administration of placebo or diclofenac.
Study details
- Official title
- Analgesic Effect of a New Metamizol Oral Pharmaceutical Form for the Treatment of the Neoplastic Chronic Pain: Randomized, Double-blind Crossover Clinical Trial Between Metamizol, Diclofenac and Placebo
- Conditions
- Interventions
- Drug: Metamizole
- Drug: Diclofenac
- Drug: Diclofenac placebo
- Drug: Metamizole placebo
- Sponsor
- Boehringer Ingelheim
- Start date
- 2000-03
- Primary completion
- 2000-11
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Total sites listed
- 0
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Hospitalized patients with neoplastic chronic pain requiring morphine treatment Exclusion Criteria: * Karnofsky index less than 30%
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT02181920